濮阳东方妇科口碑很高濮阳东方妇科医院在哪里,濮阳东方妇科医院评价很高,濮阳东方男科电话多少,濮阳东方医院治疗阳痿很便宜,濮阳东方医院治疗早泄收费公开,濮阳东方男科医院割包皮手术收费便宜不,濮阳东方医院看妇科收费正规

SAN DIEGO (KGTV) — As reports surfaced that the Alliance of American Football would suspend all league operations, its teams — and fans — were left in a state of limbo.Fans searching for tickets to the San Diego Fleet's April 14 game at SDCCU Stadium against the Arizona Hotshots were met with a screen reading, "Oh-no! These tickets went fast and we're unable to find more right now."Calls to season ticket lines and links on the team's website went unanswered and returned no results Tuesday. A note was also left on the team's office door at SDCCU Stadium reading, "We're closed for the remainder of the day."According to the team's general manager, Tuesday practice had been canceled, but no further statement on the league's reported decision was given.RELATED: Alliance of American Football to suspend operations immediately, reports sayThe Fleet, as well as the AAF's seven other teams, had played eight of 10 regular season games slated for the league's inaugural season. According to The Action Network's Darren Rovell, AAF Chairman Tom Dundon had funded the league week-to-week and will lose about million of his investment. Tuesday's decision was reportedly made against the wishes of league co-founders Charlie Ebersol and Bill Polian. 1260

SAN DIEGO (KGTV) — As people continue to wipe out store shelves and stock up on essential items, a new app called Markk is helping users locate where products like water, eggs, and toilet paper are actually in stock."I think the main thing that makes us happy, is it's helping people out there," said co-founder, Shachin Bharadwaj.What started off as a visual, real-time review app in late August, quickly pivoted to an emergency supply finder amid the coronavirus pandemic.RELATED: San Diego grocery stores hiring to address demand amid virus"You can take photos and videos of the store with items you want to focus on," said Bharadwaj.Markk gives users the ability to take pictures or videos of the in stock essential items, in real-time, then tag their location and post."It's like an Instagram story basically," said Bharadwaj.RELATED: Will you qualify for a ,200 COVID-19 stimulus check?Your location must be enabled while using the app, but it only shows up to other users when posting from a store.The pictures or videos get marked on a map and may stay there for up to 24 hours."If you see new users coming into the same place and giving a better marking, the older marking automatically expires," explained Bharadwaj.RELATED: Grocery stores with hours for seniors amid coronavirus pandemicYou can also let users know what's out of stock, saving your neighbors a trip and reducing crowding in grocery stores."If you can help people in the community report essentials, when you are out buying stuff for yourself, then I think you are helping the greater cause," he said.This is only the third week the emergency supply finder has been in use, it is available worldwide but have mostly been used in Los Angeles.RELATED: 3.3 million seek US jobless aid, nearly 5 times earlier highBharadwak is hoping to get the word out so neighbors can begin helping each other during this unusual time."It will really help the community kind of be stronger and bring something for each other," he said.Markk is available in the Apple App Store as well as the Google Play Store. 2078

SAN DIEGO (KGTV) - Coronavirus vaccine trials are underway, but it's unlikely you'll be able to get one before next year.ABC 10News spoke with Dr. Anthony Fauci, the Director of the National Institute of Allergy and Infectious Diseases, about the next steps in the battle against the Coronavirus.Team 10 investigative reporter Adam Racusin asked Dr. Fauci when a safe and effective vaccine will be available."Well, Adam, we're hoping that's going to be as we get toward the end of this calendar year late fall early winter," he said. "In the United States, two candidates have already started a phase three trial. They started last week on July 27."Fauci said in the next few months, other companies will be getting into a phase three trial."We hope, and I think we can be cautiously optimistic about this, that we will have a safe and effective vaccine by the end of the year, beginning of 2021," he said. "There's never a guarantee Adam, and that's why you do the trials, and the phase three trials are about 30,000 people."Dr. Fauci explained that the government has invested hundreds of millions of dollars - if not billions on vaccine production even before they know if it will work. So, if it is valid, in early 2021, there could be tens of millions of doses ready to go.As for who'd get it first, Fauci said they have committees that advise the Centers for Disease Control and Prevention. They're also adding an extra layer of individuals from the National Academy of Medicine to complement that decision."The prioritization is usually for those who would benefit the most and need it the most such as health care providers, those who are vulnerable, the elderly, those with underlying conditions including minority individuals who we know disproportionately suffer much more both in infection rate and in serious consequences," Fauci said.But even if the vaccine is approved, the speed at which it'll be done makes some people cautious and even uncomfortable. Others have indicated they are against any vaccine."We're having what's called community engagement and community involvement," Fauci said. "This has been very successful when we had interventions during the earlier years of HIV/AIDS when there was some skepticism in the community about safety and efficacy in drugs. So we're going to get community leaders to help us get out there and be very transparent in outreaching to the various communities, including minority communities, that may have some skepticism to getting vaccinated."The vaccine is months away at a minimum, yet positive cases are still rising in some communities.Dr. Fauci said what's concerning to him is the capability of the virus to be efficient in how it spreads from person to person."We've got to take it seriously," he warned.Team 10 investigator Adam Racusin asked Fauci, while the country is waiting for a vaccine, does he believe school-aged kids should be physically in school.“Well, I think they should be what we call an overriding default position,” Fauci said. “That it is better, and we should try to the best of our ability to get the children back to school because of the deleterious effects to the children when they’re not in school and the ripple effects to parents of having to stop work to take care of them. However, and I underline the ‘however,’ this should not be sacrificing the health, the welfare or the safety of the children as well as the teachers.”He continued, “So we live in a big country, and you’ve got to realize that there are some areas locally where the infection is so low that you can get the kids back to school, no problem. You’ve got to be realizing and flexible that there are some areas of the country where the infection activity is so high that locally the individual people responsible may have to make the decision either to not get the kids back to school or to do it in a way that safeguards the children’s health by hybrid between online and in-person, physical separation, indoor-outdoor, morning afternoon. There are a lot of ways to do that. We have to be flexible. It’s not one size fits all with getting the children back to school.”To learn more about the clinical trials or to volunteer: https://www.coronaviruspreventionnetwork.org/ 4244

SAN DIEGO (KGTV) — As the world waits for a vaccine against the coronavirus, two San Diego biotechs are teaming up to develop a nasal spray using designer antibodies cloned from COVID-19 survivors.About 70 companies worldwide are working on therapies for COVID-19 using cloned antibodies, according to an estimate by the International AIDS Vaccine Initiative. A few of these treatments, known officially as monoclonal antibody therapies, have advanced to clinical trials.Most require an injection, but San Diego-based Diomics and its partner Active Motif, based in Carlsbad, are developing a once-a-day spray that could be easily self-administered.Early research suggests the coronavirus primarily enters the body through the nose. The spray, called Dioguard, is designed to coat the lining of the nasal cavity with cloned antibodies that are held in place for 24 hours or more using a proprietary polymer material developed by Diomics.Diomics CEO Anthony Zolezzi said he believes the spray “holds the key to allowing many aspects of life to resume until the day comes when there’s an effective vaccine in widespread use.”Diomics is also developing two tests for COVID-19 antibodies using its polymer beads, including a device that looks like a nicotine patch that is designed to monitor for infections for a week or more.RELATED: How a dot on your forearm could be the future sign of COVID immunityActive Motif is providing the cloned antibodies for the nasal spray. With a lab in Shanghai and other relationships in China, the Carlsbad company was able to clone antibodies from 11 Chinese survivors in February, before the World Health Organization declared a pandemic.When the company started the cloning project, they thought the virus would probably disappear in three to six months, said Active Motif CEO Ted DeFrank. “Then people started realizing, no this is going to be with us for a while.”The plasma from the 11 Chinese patients contained thousands of antibodies, and scientists with Active Motif set about selecting the one that was most effective, dubbed 414-1. The company says it can neutralize SARS-CoV-2 virus particles with 98 percent effectiveness.Monoclonal antibodies have some similarities to convalescent plasma, which is a complex cocktail of antibodies and other immune molecules drawn from the blood of recovered patients. One of the key differences is that cloned antibodies can be mass produced in a lab.Cloned antibodies have been used in treatments for more than 30 years, primarily for cancer. One such treatment famously helped former U.S. President Jimmy Carter beat melanoma.But of the more than 100 monoclonal antibody therapies licensed for use, only seven are for communicable diseases, according to IAVI.Historically, the treatments have been expensive and difficult to produce, but Diomics said it’s targeting a price of about a spray for Dioguard, roughly per bottle.“We do not want to have huge profits from a pandemic, that’s just wrong,” Zolezzi said. “We’re going to price this as effectively as we can for the masses. We want to get this out to the masses.”Animal testing is about to begin and the companies said they hope to progress to human trials soon. Their goal is to release the spray in early 2021, when a vaccine may be on the market but not yet widely available.If the spray works, it could be adapted to other viruses to help fight future pandemics, Zolezzi said."That’s our real goal," Zolezzi said. "That we never get caught flat-footed like this time." 3526

SAN DIEGO (KGTV) — As Pfizer’s COVID-19 vaccine begins circulating, there is another big logistical challenge ahead: reminding people to get the second dose.Both vaccines developed by Pfizer and Moderna require two doses spaced several weeks apart. People who get immunized often feel fatigue or soreness shortly after the shot and may experience fever, particularly after the second dose, according to clinical trial data.Doctors say those immediate, short-term side effects are a positive sign the immune system is revving up production.The side effects are similar to that of the shingles vaccine. But studies show about 20 percent of the people who get the shingles vaccine skip the second dose.Experts say if that happens with the COVID vaccines, there could be consequences.The worst-case-scenario is that skipping the second shot could allow the virus to spread and mutate, and potentially build resistance to the vaccines, according to Penn State University biologist David Kennedy.That outcome is considered unlikely, but the World Health Organization announced Monday it detected a new variation of the virus in England, showing the virus is already mutating without the evolution pressure of a mass vaccine program.“Does this make the virus more serious? Does it allow the virus to transmit more easily? Does it interfere with diagnostics? Would it interfere with vaccine effectiveness? These are questions. None of these questions have been addressed yet,” said Dr. Michael Ryan, director of the WHO Health Emergencies Program.When administered in two doses, Pfizer’s vaccine is 95 percent effective at preventing COVID-19 symptoms. The FDA’s review showed the vaccine could be up to 52 percent effective after a single dose, but the data was limited.“I think you could probably say you’re going to have short-lived but incomplete protection,” said vaccine expert Dr. Paul Offit. “Protection from disease but possibly not asymptomatic shedding.”It remains unclear whether people who are fully immunized against the virus can still spread it to others asymptomatically but someone who is only partially immunized may be especially prone to silent spread, according to Offit.When Americans roll up their sleeves to get the COVID-19 vaccine, they’ll get a 4 by 6 inch index card from the CDC noting which brand they got, the lot number, and when they’re due for the second shot.People who get Pfizer’s vaccine need to get a second shot 21 days later. People who get Moderna’s need to wait 28 days for round two.The CDC is encouraging people to photograph their card with their cell phone as a backup, because beyond the index card, the logistics of reminding people about their second dose will vary by state and healthcare provider.In California’s draft vaccination plan from October, the state said it was exploring ways to "systematically text, email, and/or auto-call individuals when their second dose is needed." The California Department of Public Health did not immediately respond to a request for comment about its latest plans.Much of the work may fall to the healthcare providers who administer the shots. Although the vaccine will be free for individuals, the government is paying providers for every first dose they give and for every second dose, a way to incentivize providers to keep close tabs on patients.However, only about 25 percent of the nation’s vaccination providers have systems that can send automated reminders, according to L.J Tan, the chief strategy officer of the Immunization Action Coalition. 3552